ReviewFrontiers in neuroscience2025
Research progress on brain network imaging biomarkers of subjective cognitive decline.
Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Exploring the changes in functional connectivity of the limbic system in Patients with amnestic mild cognitive impairment treated by acupuncture based on fMRI.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Subjective cognitive decline (SCD) is an early manifestation of the Alzheimer's disease (AD) continuum, and accurately diagnosing SCD to differentiate it from neurotypical aging in older adults is a common challenge for researchers. Methods: This review examines and summarizes relevant studies regarding the neuroimaging of the AD continuum, and comprehensively summarizes and outlines the SCD clinical features characterizing along with the corresponding neuroimaging changes involving structural, functional, and metabolic networks. Results: The clinical characteristics of SCD include a subjective decline in self-perceived cognitive function, and there are significant imaging changes, such as reductions in gray matter volume in certain brain regions, abnormalities in the integrity of white matter tracts and diffusion metrics, alterations in functional connectivity between different sub-networks or within networks, as well as abnormalities in brain metabolic networks and cerebral blood flow perfusion. Conclusion: The 147 referenced studies in this paper indicate that exploring the structural, functional, and metabolic network changes in the brain related to SCD through neuroimaging aims to enhance the goals and mission of brain science development programs: "Understanding the Brain," "Protecting the Brain," and "Creating the Brain," thereby strengthening researchers' investigation into the mechanisms of brain function. Early diagnosis of SCD, along with prompt intervention, can reduce the incidence of AD spectrum while improving patients' quality of life, even integrating numerous scientific research achievements into unified and established standards and applying them in clinical practice by doctors, thus all encouraging researchers to further investigate SCD issues in older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.